Development and uses for monoclonal antibodies to chemoattractant receptors

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Monoclonal antibodies (mAbs) serve as research reagents, for dissecting the biology of chemokine and chemoattractant receptors. However mAbs are also an attractive class of therapeutic, because they are able to block large protein-protein interactions, and are generally easier and more predictable for clinical development. mAbs are also capable of depleting leukocyte subsets, such as pathogenic cell types, through processes such as phagocytosis, complement fixation and ADCC. Chemokine receptors are probably one of the best classes of molecules for marking different leukocyte subsets, such as Th1, Th2, Th17 and Tfh cells, and hence should provide a means for selective depletion. This short review will discuss the uses of mAbs to chemoattractant receptors, as research reagents and as therapeutics.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalCurrent Immunology Reviews
Volume8
Issue number2
DOIs
Publication statusPublished - May 2012

Keywords

  • C5aR
  • Immunotherapy
  • Leukocyte depletion
  • Monoclonal antibodies

Cite this

@article{6d87300f6e9d438da2eec2a887a615dc,
title = "Development and uses for monoclonal antibodies to chemoattractant receptors",
abstract = "Monoclonal antibodies (mAbs) serve as research reagents, for dissecting the biology of chemokine and chemoattractant receptors. However mAbs are also an attractive class of therapeutic, because they are able to block large protein-protein interactions, and are generally easier and more predictable for clinical development. mAbs are also capable of depleting leukocyte subsets, such as pathogenic cell types, through processes such as phagocytosis, complement fixation and ADCC. Chemokine receptors are probably one of the best classes of molecules for marking different leukocyte subsets, such as Th1, Th2, Th17 and Tfh cells, and hence should provide a means for selective depletion. This short review will discuss the uses of mAbs to chemoattractant receptors, as research reagents and as therapeutics.",
keywords = "C5aR, Immunotherapy, Leukocyte depletion, Monoclonal antibodies",
author = "Mackay, {Charles R.}",
year = "2012",
month = "5",
doi = "10.2174/157339512800099729",
language = "English",
volume = "8",
pages = "149--153",
journal = "Current Immunology Reviews",
issn = "1573-3955",
publisher = "Bentham Science Publishers",
number = "2",

}

Development and uses for monoclonal antibodies to chemoattractant receptors. / Mackay, Charles R.

In: Current Immunology Reviews, Vol. 8, No. 2, 05.2012, p. 149-153.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Development and uses for monoclonal antibodies to chemoattractant receptors

AU - Mackay, Charles R.

PY - 2012/5

Y1 - 2012/5

N2 - Monoclonal antibodies (mAbs) serve as research reagents, for dissecting the biology of chemokine and chemoattractant receptors. However mAbs are also an attractive class of therapeutic, because they are able to block large protein-protein interactions, and are generally easier and more predictable for clinical development. mAbs are also capable of depleting leukocyte subsets, such as pathogenic cell types, through processes such as phagocytosis, complement fixation and ADCC. Chemokine receptors are probably one of the best classes of molecules for marking different leukocyte subsets, such as Th1, Th2, Th17 and Tfh cells, and hence should provide a means for selective depletion. This short review will discuss the uses of mAbs to chemoattractant receptors, as research reagents and as therapeutics.

AB - Monoclonal antibodies (mAbs) serve as research reagents, for dissecting the biology of chemokine and chemoattractant receptors. However mAbs are also an attractive class of therapeutic, because they are able to block large protein-protein interactions, and are generally easier and more predictable for clinical development. mAbs are also capable of depleting leukocyte subsets, such as pathogenic cell types, through processes such as phagocytosis, complement fixation and ADCC. Chemokine receptors are probably one of the best classes of molecules for marking different leukocyte subsets, such as Th1, Th2, Th17 and Tfh cells, and hence should provide a means for selective depletion. This short review will discuss the uses of mAbs to chemoattractant receptors, as research reagents and as therapeutics.

KW - C5aR

KW - Immunotherapy

KW - Leukocyte depletion

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=84860273921&partnerID=8YFLogxK

U2 - 10.2174/157339512800099729

DO - 10.2174/157339512800099729

M3 - Review Article

AN - SCOPUS:84860273921

VL - 8

SP - 149

EP - 153

JO - Current Immunology Reviews

JF - Current Immunology Reviews

SN - 1573-3955

IS - 2

ER -